Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study

Table 3 Summary of response rates to vinorelbine-based salvage treatments

Response	Overall	Single agent vinorelbine	Vinorelbine + other chemotherapies	Continuing trastuzumab	Stopping Trastuzumab
	N60	N 39¹	N 21	N 29	N 31
ORR	17 (28%)	9 (23%)	8 (38%)²	6 (21%)	11 (36%)³
CR	1 (2%)	0 (0%)	1 (5%)	0 (0%)	1 (3%)
PR	16 (27%)	9 (23%)	7 (33%)	6 (21%)	10 (32%)
SD	16 (27%)	12 (31%)	4 (19%)	8 (28%)	8 (26%)
PD	27 (45%)	18 (46%)	9 (43%)	15 (52%)	12 (39%)
CB (CR+PR+SD ≥ 6 months)	30 (50%)	15 (38%)	11 (52%)	13 (48%)	18 (58%)

ORR; overall response rate (CR+ PR); CR, complete remission: PR, partial response; SD, stable disease; PD, progressive disease; CB, clinical benefit
¹26 of these patients received single-agent chemotherapy with vinorelbine and continued trastuzumab beyond progression
²Two tailed Fisher's Exact test for the difference in ORR (CR+PR) = 0.24
³ Two tailed Fisher's Exact test for the difference in ORR (CR+PR) = 0.26

ISSN: 1471-2407